Non-invasive detection of drug toxicity in rats by solid-phase extraction and MALDI-TOF analysis of urine samples

Analytical and Bioanalytical Chemistry

Volumn 405, Issue 7, 2013, Pages 2311-2320

  Iloro, Ibon ^a   Gonzalez, Esperanza ^b   Gutierrez De Juan, Virginia ^b   Mato, Jose M ^b   Falcon Perez, Juan M ^b,c   Elortza, Felix ^a  

^a CIC BIOGUNE   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c BASQUE FOUNDATION FOR SCIENCE   (Spain)

Author keywords

Drug induced injury; MALDI TOF profiling; Solid phase extraction; Systems toxicology; Urine peptidomics

Indexed keywords

DRUG-INDUCED INJURY; MALDI-TOF; PEPTIDOMICS; SOLID-PHASE EXTRACTION; SYSTEMS TOXICOLOGIES;

ACCIDENT PREVENTION; DIAGNOSIS; ESCHERICHIA COLI; MASS SPECTROMETRY; PHASE SEPARATION; TOXICITY;

EXTRACTION;

CARBON TETRACHLORIDE; GALACTOSAMINE; LIPOPOLYSACCHARIDE;

ANIMAL; ARTICLE; EVALUATION; ISOLATION AND PURIFICATION; MALE; MASS SPECTROMETRY; METHODOLOGY; RAT; SOLID PHASE EXTRACTION; URINE; WISTAR RAT;

ANIMALS; CARBON TETRACHLORIDE; GALACTOSAMINE; LIPOPOLYSACCHARIDES; MALE; RATS; RATS, WISTAR; SOLID PHASE EXTRACTION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

ESCHERICHIA COLI; RATTUS;

EID: 84878298880     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-012-6644-9     Document Type: Article

References (34)

1. Kaplowitz N (2001) Drug-induced liver disorders: implications for drug development and regulation. Drug Saf 24(7):483-490
2. Dimasi JA, Hansen RW, Grabowski HG (2008) Misleading congress about drug development: reply. J Health Polit Policy Law 33(2):319-324. doi: 10.1215/03616878-2007-063, discussion 325-317
3. Ozer J, Ratner M, Shaw M, Bailey W, Schomaker S (2008) The current state of serum biomarkers of hepatotoxicity. Toxicology 245(3):194-205. doi: 10.1016/j.tox.2007.11.021
4. Muller PY, Dieterle F (2009) Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring. Expert Opin Drug Metab Toxicol 5(9):1023-1038. doi: 10.1517/17425250903114174
5. Albitar M, Potts SJ, Giles FJ, O'Brien S, Keating M, Thomas D, Clarke C, Jilani I, Aguilar C, Estey E, Kantarjian H (2006) Proteomic-based prediction of clinical behavior in adult acute lymphoblastic leukemia. Cancer 106(7):1587-1594. doi: 10.1002/cncr.21770
6. Petricoin EF, Liotta LA (2004) SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol 15(1):24-30. doi: 10.1016/j.copbio.2004.01.005S0958166904000072
7. Callesen AK, Vach W, Jorgensen PE, Cold S, Tan Q, Depont Christensen R, Mogensen O, Kruse TA, Jensen ON, Madsen JS (2008) Combined experimental and statistical strategy for mass spectrometry based serum protein profiling for diagnosis of breast cancer: a case-control study. J Proteome Res 7(4):1419-1426. doi: 10.1021/pr7007576
8. Villanueva J, Philip J, Entenberg D, Chaparro CA, Tanwar MK, Holland EC, Tempst P (2004) Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal Chem 76(6):1560-1570. doi: 10.1021/ac0352171
9. Kaleta EJ, Clark AE, Cherkaoui A, Wysocki VH, Ingram EL, Schrenzel J, Wolk DM (2011) Comparative analysis of PCR-electrospray ionization/mass spectrometry (MS) and MALDI-TOF/MS for the identification of bacteria and yeast from positive blood culture bottles. Clin Chem 57(7):1057-1067
10. Putignani L, Del Chierico F, Onori M, Mancinelli L, Argentieri M, Bernaschi P, Coltella L, Lucignano B, Pansani L, Ranno S, Russo C, Urbani A, Federici G, Menichella D (2011) MALDI-TOF mass spectrometry proteomic phenotyping of clinically relevant fungi. Mol Biosyst 7(3):620-629. doi: 10.1039/c0mb00138d
11. Ferreira L et al (2010) Identification of Brucella by MALDI-TOF mass spectrometry. Fast and reliable identification from agar plates and blood cultures. PLoS One 5(12):14235. doi: 10.1371/journal.pone.0014235
12. Decramer S, Gonzalez de Peredo A, Breuil B, Mischak H, Monsarrat B, Bascands JL, Schanstra JP (2008) Urine in clinical proteomics. Mol Cell Proteomics 7(10):1850-1862
13. Tomosugi N, Kawabata H, Wakatabe R, Higuchi M, Yamaya H, Umehara H, Ishikawa I (2006) Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System. Blood 108(4):1381-1387. doi: 10.1182/blood-2005-10- 4043
14. Theodorescu D, Wittke S, Ross MM, Walden M, Conaway M, Just I, Mischak H, Frierson HF (2006) Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol 7(3):230-240. doi: 10.1016/S1470-2045(06)70584-8
15. Pisitkun T, Johnstone R, Knepper MA (2006) Discovery of urinary biomarkers. Mol Cell Proteomics 5(10):1760-1771. doi: 10.1074/mcp.R600004-MCP200
16. Zimmerli LU, Schiffer E, Zurbig P, Good DM, Kellmann M, Mouls L, Pitt AR, Coon JJ, Schmieder RE, Peter KH, Mischak H, Kolch W, Delles C, Dominiczak AF (2008) Urinary proteomic biomarkers in coronary artery disease. Mol Cell Proteomics 7(2):290-298. doi: 10.1074/mcp.M700394-MCP200
17. Kaiser T, Kamal H, Rank A, Kolb HJ, Holler E, Ganser A, Hertenstein B, Mischak H, Weissinger EM (2004) Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation. Blood 104(2):340-349. doi: 10.1182/blood-2004-02-0518
18. El-Kasti MM, Wright C, Fye HK, Roseman F, Kessler BM, Becker CM (2011) Urinary peptide profiling identifies a panel of putative biomarkers for diagnosing and staging endometriosis. Fertil Steril 95(4):1261-1266. doi: 10.1016/j.fertnstert.2010.11.066, e1261-1266
19. Thongboonkerd V, Malasit P (2005) Renal and urinary proteomics: current applications and challenges. Proteomics 5(4):1033-1042. doi: 10.1002/pmic.200401012
20. Schaub S, Wilkins J, Weiler T, Sangster K, Rush D, Nickerson P (2004) Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int 65(1):323-332. doi: 10.1111/j.1523-1755.2004.00352.x
21. Fiedler GM, Baumann S, Leichtle A, Oltmann A, Kase J, Thiery J, Ceglarek U (2007) Standardized peptidome profiling of human urine by magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem 53(3):421-428
22. Thongboonkerd V (2007) Practical points in urinary proteomics. J Proteome Res 6(10):3881-3890. doi: 10.1021/pr070328s
23. Fujii T, Fuchs BC, Yamada S, Lauwers GY, Kulu Y, Goodwin JM, Lanuti M, Tanabe KK (2010) Mouse model of carbon tetrachloride induced liver fibrosis: histopathological changes and expression of CD133 and epidermal growth factor. BMC Gastroenterol 10:79. doi: 10.1186/1471-230X-10-79
24. Keppler D, Lesch R, Reutter W, Decker K (1968) Experimental hepatitis induced by d-galactosamine. Exp Mol Pathol 9(2):279-290
25. Morrison DC, Ryan JL (1987) Endotoxins and disease mechanisms. Annu Rev Med 38:417-432. doi: 10.1146/annurev.me.38.020187.002221
26. Reiser J, Mundel P (2009) Is the LPS-mediated proteinuria mouse model relevant to human kidney disease? Nat Med 15(2):133-134
27. Zhang X, Leung SM, Morris CR, Shigenaga MK (2004) Evaluation of a novel, integrated approach using functionalized magnetic beads, bench-top MALDI-TOF-MS with prestructured sample supports, and pattern recognition software for profiling potential biomarkers in human plasma. J Biomol Tech 15(3):167-175
28. Sekiyama E, Matsuyama Y, Higo D, Nirasawa T, Ikegawa M, Kinoshita S, Tashiro K (2008) Applying magnetic bead separation/MALDI-TOF mass spectrometry to human tear fluid proteome analysis. J Proteomics Bioinform 1:368-373
29. Chen J, Wang W, Lv S, Yin P, Zhao X, Lu X, Zhang F, Xu G (2009) Metabonomics study of liver cancer based on ultra performance liquid chromatography coupled to mass spectrometry with HILIC and RPLC separations. Anal Chim Acta 650(1):3-9. doi: 10.1016/j.aca.2009.03.039
30. Shariff MI, Ladep NG, Cox IJ, Williams HR, Okeke E, Malu A, Thillainayagam AV, Crossey MM, Khan SA, Thomas HC, Taylor-Robinson SD (2010) Characterization of urinary biomarkers of hepatocellular carcinoma using magnetic resonance spectroscopy in a Nigerian population. J Proteome Res 9(2):1096-1103. doi: 10.1021/pr901058t
31. Weber LW, Boll M, Stampfl A (2003) Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit Rev Toxicol 33(2):105-136. doi: 10.1080/713611034
32. Koff RS, Fitts JJ, Sabesin SM, Zimmerman HJ (1971) d-galactosamine hepatotoxicity. II. Mechanism of fatty liver production. Proc Soc Exp Biol Med 138(1):89-92
33. Medline A, Schaffner F, Popper H (1970) Ultrastructural features in galactosamine-induced hepatitis. Exp Mol Pathol 12(2):201-211
34. Miyahara M, Enzan H, Shiraishi N, Kawase M, Yamamoto M, Hara H, Utsumi K (1982) Mitochondrial damage in galactosamine-induced liver intoxication in rats. Biochim Biophys Acta 714(3):505-515